Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Deloitte
Argus Health
US Department of Justice
Baxter
Cipla
Fuji
McKinsey
Fish and Richardson

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050709

« Back to Dashboard

NDA 050709 describes PROGRAF, which is a drug marketed by Astellas and is included in two NDAs. It is available from two suppliers. Additional details are available on the PROGRAF profile page.

The generic ingredient in PROGRAF is tacrolimus. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.
Summary for 050709
Tradename:PROGRAF
Applicant:Astellas
Ingredient:tacrolimus
Patents:0
Therapeutic Class:Dermatological Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 050709
Mechanism of ActionCalcineurin Inhibitors
Medical Subject Heading (MeSH) Categories for 050709
Suppliers and Packaging for NDA: 050709
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROGRAF tacrolimus INJECTABLE;INJECTION 050709 NDA Astellas Pharma US, Inc. 0469-3016 N 0469-3016-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 5MG BASE/ML
Approval Date:Apr 8, 1994TE:APRLD:Yes

Expired US Patents for NDA 050709

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas PROGRAF tacrolimus INJECTABLE;INJECTION 050709-001 Apr 8, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Citi
Chinese Patent Office
Queensland Health
Harvard Business School
McKinsey
Cipla
Federal Trade Commission
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.